STO · SPRINT.ST
Sprint Bioscience AB
SEK 3.50+SEK 0.06 (+1.74%)
Sprint Bioscience AB’s quoted price sits in the upper half of its reported 52-week range, 23.75% below the high.
Loading market information…
STO · SPEC.ST · SEK
Stock price, earnings
Quote as of Oct 29, 2026, 04:12 PM UTC. Cached market data; not a live quote.
One-year closing-price history · SEK. Historical prices are not a forecast.
SpectraCure AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 93.5% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow SpectraCure AB (publ)’s reporting calendar.
THE COMPANY BEHIND THE TICKER
SpectraCure AB (publ) specializes in oncology, developing innovative cancer treatments that harness laser light and photodynamic agents. A cornerstone of their research is the IDOSE software, which powers an interstitial photodynamic therapy (PDT) system. This cutting-edge system is currently in Phase II clinical trials, where its efficacy in addressing solid tumors is being evaluated. The Swedish company, established in Lund in 2003, continues to advance its therapeutic solutions.
Latest available per-share figures in SEK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:10 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 3.50+SEK 0.06 (+1.74%)
Sprint Bioscience AB’s quoted price sits in the upper half of its reported 52-week range, 23.75% below the high.
SEK 0.13+SEK 0.00 (+2.88%)
Simris Alg AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 35.9% below the high.
SEK 16.70-SEK 0.20 (-1.18%)
Scandinavian Real Heart AB (Publ)’s quoted price sits in the lower half of its reported 52-week range, 29.54% below the high.
SEK 1.25SEK 0.00 (0.0%)
Iconovo AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 31.69% below the high.
SEK 0.33-SEK 0.00 (-0.6%)
IDL Diagnostics AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 37.17% below the high.
SEK 0.06-SEK 0.00 (-2.47%)
Episurf Medical AB’s quoted price sits in the lower half of its reported 52-week range, 79.55% below the high.
SEK 0.56SEK 0.00 (0.0%)
ScandiDos AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 57.58% below the high.
SEK 0.04+SEK 0.00 (+0.5%)
Spago Nanomedical AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 80.95% below the high.
